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Table. Unadjusted One-year Ischemic Event Rates Stratiﬁed by Presence or
Absence of Baseline Thrombocytopenia
Platelets
<150,000
(N [ 573)
Platelets
‡150,000
(N [ 9,996)
p-value
MACE 119 (21.3) 1458 (15.6) <0.0001
Death 36 (6.7) 320 (3.6) <0.0001
Cardiac death 20 (3.9) 205 (2.2) 0.02
Non-cardiac death 11 (2.0) 91 (1.0) 0.01
Myocardial infarction 53 (9.5) 716 (7.5) 0.06
Q wave infarction 13 (2.3) 173 (1.9) 0.34
Non-Q wave infarction 41 (7.4) 553 (5.7) 0.09
Target vessel
revascularization
61 (11.1) 786 (8.5) 0.01
Target lesion
revascularization
53 (9.6) 655 (7.2) 0.01
Deﬁnite/probable stent 15 (2.7) 228 (2.5) 0.63
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randomized 1498 patients with STEMI undergoing percutaneous coronary interven-
tion (PCI) to EES or BMS. For the purpose of this substudy, the patient-oriented
combined endpoint of all-cause death, any recurrent myocardial infarction and any
revascularization, target lesion revascularization and stent thrombosis rates were
analyzed according to the gender at 2-year follow-up.
Results: Out of 1498 patients included in the trial, 254 (17.0%) women were included
and randomized to BMS (n¼137, 53.9%) or EES (n¼117, 46.1%). Women were older
(67.9 vs. 59.8; p<0.01), had higher prevalence of hypertension (62.2% vs. 45.6%;
p<0.01) and a lower prevalence of smoking (36.6% vs. 79.5%; p<0.01) as compared
with men. Also women had a lower use of thrombectomy (59.1% vs. 66.4%; p¼0.02)
and IIb/IIIa inhibitor than men (44.9% vs. 53.9%, p<0.01). In contrast with men, stent
diameter was smaller in women (3.07 mm vs. 3.23 mm, p<0.01). Compliance of dual
antiplatelet therapy at one year was lower in women than in men. After adjustment per
confounders, the primary endpoint was similar between men and women (HR 0.95;
95%CI 0.66-1.37) and within women, between those treated with BMS versus EES
(HR 1.54: 95%CI 0.77-3.11). Women showed a lower rate of repeat revascularization
than men (HR 0.55; 95%CI 0.32-0.95) despite worse baseline characteristics. The
difference was driven by an outperformance of EES in women. No differences in
deﬁnitive/probable stent thrombosis (1.2% vs. 2.0% HR 0.58; 95%CI 0.17-1.94) was
observed between women and men.
Conclusions: Our substudy may suggest that EES would have a more potent anti-
proliferative effect in women suffering from STEMI as compared to men without any
safety concerns.
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Background: Intraprocedural thrombotic events (IPTE) during percutaneous coronary
intervention (PCI) are associated with adverse outcomes in patients with both non-ST-
segment elevation and ST-segment elevation acute coronary syndromes (NSTEACS/
STEMI). We have previously validated the occurrence of IPTE to be a powerful
independent predictor of early and late major adverse cardiac events (MACE) after
PCI. The extent to which individual components of IPTE are associated with adverse
events is unknown.
Methods: A total of 6,591 patients who received PCI for NSTEACS/STEMI in the
Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) and
Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial
Infarction (HORIZONS-AMI) trials underwent detailed frame-by-frame core labora-
tory angiographic analysis to assess for IPTE. IPTE was deﬁned as the occurrence of
new/worsened thrombus, abrupt closure, no reﬂow/slow ﬂow, distal embolization, or
intraprocedural stent thrombosis (IPST). The independent associations of IPTE
components with death, major bleeding, and MACE at 30-days were assessed using
multivariable models.
Results: The overall incidence of IPTE was 7.8%. Among patients with IPTE, no
reﬂow/slow reﬂow was present in 58.0%, new/worsened thrombus in 35.3%, distal
embolization in 34.9%, abrupt closure in 19.8%, and IPST in 9.5% of patients. Each
IPTE component was associated with 30-day death, major bleeding, and MACE in
multivariable models (Table), with the strongest association observed for IPST.Table. Multivariate Associations of 30-day Clinical Outcomes 1 2
IPTE Component
30-day Clinical Outcome
MACE Major Bleeding Death
HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value
IPTE any 2.31 [1.76,
3.05]
<0.0001 1.94 [1.45,
2.60]
<0.0001 3.66 [2.21,
6.08]
<0.0001
New/worsened
thrombus
2.23 [1.46,
3.41]
0.0002 2.32 [1.52,
3.55]
<0.0001 5.72 [3.01,
10.86]
<0.0001
Abrupt closure 2.98 [1.98,
4.46]
0.0001 3.01 [2.00,
4.52]
<0.0001 4.83 [2.42,
9.67]
<0.0001
No reﬂow/slow
ﬂow
2.80 [2.00,
3.93]
<0.0001 2.04 [1.39,
2.99]
0.0003 4.24 [2.33,
7.72]
<0.0001
Distal
embolization
2.26 [1.48,
3.45]
0.0002 2.03 [1.31,
3.16]
0.0016 4.31 [2.15,
8.62]
<0.0001
IPST 6.21
[3.63,10.59]
<0.0001 4.81 [2.64,
8.76]
<0.0001 12.30
[5.32,28.41]
<0.0001
IPTE: Intraprocedural thrombotic event; IPST ¼ Intraprocedural stent thrombosis; MACE ¼
Major adverse cardiac events; HR ¼ Hazard Ratio; CI ¼ Conﬁdence Interval.
1 adjusted for age, gender, history of diabetes, history of hypertension, hyperlipidemia, current
smoking, prior MI, baseline hematocrit, baseline WBC count
2 each row represents a separate multivariate Cox regression model
B80 JACC Vol 62/18/Suppl B j October 2Conclusions: The occurrence of IPTE is not infrequent among high-risk ACS patients
undergoing PCI. The single component with the strongest association with adverse
events was IPST, which fortunately represented <10% of IPTE events overall. Future
therapeutic strategies aimed at minimizing the occurrence and consequences of IPTE
are warranted.
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Background: While acquired TP has consistently been associated with short- and
long-term adverse outcomes after PCI, the impact of baseline TP, however, has not
been as thoroughly investigated.
Methods: Data from 10,569 pts presenting with NSTEACS or STEMI in whom PCI
was performed was pooled from 2 large-scale randomized trials, ACUITY and
HORIZONS. Outcomes were examined according to the presence of baseline TP,
deﬁned as platelet counts <150 X 103/mm3.
Results: Baseline TP was present in 573 (5.4%) pts. Patients with baseline TP were
more likely to have diabetes, hypertension, hyperlipidemia, renal dysfunction and
prior PCI and greater number of lesions and diseased vessels. The unadjusted 1-year
rate of death (6.7% vs. 3.6%, p<0.0001), MACE (21.3% vs.15.6%, p<0.0001), target
vessel revascularization (11.1% vs. 8.5%, p¼0.01) and target lesion revascularization
(TLR; 9.6% vs. 7.2%, p¼0.01) was signiﬁcantly higher in pts with baseline TP
compared with pts with no TP. By multivariable analysis, the presence of TP at
baseline was an independent predictor of 1-year death (HR [95%CI] ¼1.71 [1.09,
2.70], p¼0.02), ischemic TLR (HR [95%CI] ¼1.42 [1.07, 1.88], p¼0.02), and major
adverse cardiac events (MACE; HR ¼1.41 [1.09, 1.82], p¼0.008).
Conclusions: The presence of baseline TP in setting of NSTEACS and STEMI pts
undergoing PCI was strongly predictive of death, ischemic TLR and MACE at 1 year.thrombosis
Data presented as n (%); CABG ¼ coronary artery bypass grafting; MACE ¼ major adverse
cardiovascular events; PCI ¼ percutaneous coronary intervention.TCT-245
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Background: Women are at high risk for mortality after ST-elevation acute
myocardial infarction (STEMI). Whether sex-disparities still exist in the treatment and
mortality of patients after STEMI remains controversial. The aim of this study was to
assess recent trends in hospital mortality and in treatment modalities for patients with
STEMI according to sex.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
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extracted from hospital discharge record databases from all hospitals in Lombardia (a
Northern Italy region with high density population). Main outcome measures were in-
hospital mortality and treatment modality by sex. Treatment modalities included
medical therapy alone or an invasive approach, the latter consisting of coronary
angiography alone, percutaneous coronary intervention (PCI), or coronary artery
bypass graft surgery. Multivariable logistic regression was performed to assess the
impact of female sex and of treatment modality on mortality after adjusting for age,
and comorbidities.
Results: A total of 92807 patients with STEMI, 66.4% men and 33.6% women were
enrolled. Women were older than men (mean 75.1 yrs vs 64.1 yrs, p<0.0001) and had
a higher prevalence of chronic renal failure (p<0.001). In-hospital mortality presented
a small decrease from 7.5% in 2000 to 6.3% in 2010 among men, while it remained
higher and substantially constant over time among women (16.4% in 2000, 16.2% in
2010). The use of an invasive approach increased over time in both sexes (from 55%
in 2000 to 91% in 2010 in men and from 36% in 2000 to 70% in 2010 in women). The
use of PCI increased from 32% in 2000 to 82% in 2010 in men; and from 21% in 2000
to 57% in 2010 in women. At multivariable regression, an invasive approach (odds
ratio (OR) 0.23, 95% conﬁdence interval (CI), 0.21-0.25, p<0.001) was associated
with a signiﬁcant reduction in mortality, while female sex was not a predictor of
mortality (OR 0.96, P¼0.18).
Conclusions: In-hospital mortality remains higher in women than in men, although
female sex is not a signiﬁcant predictor of mortality. Despite temporal increases in the
use of an invasive approach, women are more often treated conservatively.
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Background: The risk for recurrent ischemic events following ST-segment elevation
myocardial infarction (STEMI) gradually declines. However, current guidelines
suggest consistent therapy from presentation out to 12 months. We sought to char-
acterize the actuarial daily ischemic risk (ADIR) in the 12 months year after STEMI.
Methods: Ischemic event rates for all 3602 patients enrolled in the prospective
HORIZONS-AMI trial were categorized according to the timing of their occurrence in
three groups: Group 1: during index hospitalization, Group 2: from hospital discharge
to 30 days, and Group 3: from 30 days post hospital discharge to 1 year. Ischemic
events included: All-cause death, cardiovascular (CV) death, non-CV death, re-
infarction (MI), deﬁnite ST and the composite of CV death, MI or deﬁnite ST. The
ADIR for each event was calculated based on the actual patient days of follow-up for
each group.
Results: Highly signiﬁcant reductions in ADIR were observed as patients transitioned
from Group 1 to Groups 2 and 3 respectively (Table). The degree of ADIR reduction
approached or exceeded a full order of magnitude for all events except for non-CV
death. Accordingly, the relative risk for the composite of CV death, MI or deﬁnite ST
was 15.20 (11.39 - 20.27, p<0.0001) for Group 1 vs. Group 2, 6.31 (4.62 - 8.62,
p<0.0001) for Group 2 vs. Group 3 and 95.94 (76.06 - 121.02, p<0.0001) for Group
1 vs. Group 3.
Conclusions: Conclusions: The risk for CV death and recurrent ischemic events
following an index STEMI treated with primary PCI dramatically declines following
hospital discharge out to the ﬁrst 30 days and declines even further between day 30
and one year. These data suggest that a tailored approach to anti-ischemic protection,
with more potent agents administered in the acute and sub-acute phases and less potent
agents (with lower bleeding potential) administered after 30 days, warrants
investigation.Table. Actuarial daily ischemic risk (ADIR) in 3 successive periods after index
hospitalization for STEMI
ENDPOINT Index hospitalization Discharge to 30 Days 30 Days to 1 year
All-cause death 78/21510 (0.3626%) 22/104397 (0.0211%) 59/1220907 (0.0048%)
CV death 71 / 21510 (0.3301%) 17 / 104397 (0.0163%) 29 / 1220907 (0.0024%)
Non-CV
death
7 / 21510 (0.0325%) 5 / 104397 (0.0048%) 30 / 1220907 (0.0025%)
Re-infarction (MI) 44 / 21510 (0.2046%) 27 / 104397 (0.0259%) 84 / 1220907 (0.0069%)
Deﬁnite ST 76 / 21510 (0.3533%) 17 / 104397 (0.0163%) 0 / 1220907 (0.0000%)
CV death + MI +
Deﬁnite ST
191 / 21510 (0.8880%) 61 / 104397 (0.0584%) 113 / 1220907 (0.0093%)
Trend p-values <0.0001 for all endpoints. All pairwise p-values <0.0001, except p¼0.16 for
Group 2 vs. Group 3 non-CV death.
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Background: We sought to analyze in ST-elevation myocardial infarction (STEMI)
patients the impact of rheolytic thrombectomy (RT) in comparison to manual
thrombus aspiration (MTA) on extension of microvascular obstruction (MVO) and
infarct size (IS) as well as on 1-year left ventricular (LV) volumes and ejection fraction
(EF) by cardiac magnetic resonance imaging (MRI).
Methods: Eighty STEMI patients (6 hours from symptom onset) reperfused by
primary angioplasty with routine abciximab therapy were randomly allocated (1:1) to
a RT or MTA. MRI was performed within 10  6 days in 37 patients (19 RT, 18
MTA), and after 1 year in 19 patients (9 RT). IS and MVO were measured 15 min
after gadolinium injection with late enhancement sequences and were analyzed
quantitatively (as percentage of the left ventricular mass –gr/LV mass-) at a core
laboratory blinded to randomization.
Results: Baseline clinical characteristics were similar between the RT and MTA
groups, as well as baseline TIMI thrombus grade (4.47  0.84 vs. 4.67  0.76,
p¼0.453). After thrombectomy, in RT compared with MTA group the thrombus grade
decreased to 1.11  1.04 vs. 2.17  1.29 (P¼0.04), and after infarct artery stenting
TIMI 3 ﬂow was 100% vs. 89% (P¼0.204), and ST-elevation resolution greater than
70% at 60 minutes was 89% vs. 72% (P¼0.198), respectively. RT compared with
MTA group did not reduced signiﬁcantly myocardial IS [12.2% (6.4-22.1) vs. 19.0%
(7-28.5) , P¼0.224] as well as the extent of MVO [0.0% (0.0-0.17) vs. 0.6% (0.0-1.4),
P¼0.117], but a trend towards a lower incidence of MVO was observed (16% vs.
44%, P¼0.056). At 1-year, the IS did not change [RT 13.2% (6.4-22.1) vs. MTA
11.4% (6.5-27.8), P¼0.253] and the recovery (baseline-1-year) of LV EF was not
different in both groups (RT 1.94.5% vs. MTA 1.18.3%, P¼0.626), with
a reduction of LV volumes found only in RT group (EDV: RT -9.315 ml vs. MTA
929.8 ml, P¼.115; ESV: RT -8.515.2 ml vs. MTA 3.120.3 ml, P¼.180,
respectively).
Conclusions: In setting of STEMI, at 1-year RT in comparison to MTA did not reduce
signiﬁcantly the IS. However a more favorable change of LV volumes were found,
likely due to a more effective thrombus removal and a lower incidence of MVO by
RT.
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Background: The optimal revascularization strategy in patients with multivessel and
left main coronary artery disease (MVD, LMD) presenting with non-ST acute coro-
nary syndrome (NSTE-ACS) is undetermined.
Methods: In this multicenter, prospective registry, 4566 patients with non-ST
elevation myocardial infarction (NSTEMI), unstable angina and MVD including LMD
were enrolled. Following angiography, 3033 patients were assigned for stenting
(10.3% DES), whereas 1533 for CABG. The complete follow-up on mortality was
obtained at 3 years.
Results: In the overall population, patients assigned for PCI were younger (64.410
vs. 65.29 p¼0.03), more frequently presented with NSTEMI (32.0 vs. 14.5%;
p¼0.01), cardiogenic shock (1.5 vs. 0.7% p<0.01) history of prior PCI (13.1 vs. 5.5%;
p<0.01) and CABG (10.6 vs. 4.6%, p<0.01). The Euroscore and TIMI risk score
were slightly higher in PCI patients (5.362.3 vs. 5.162.0 and 3.871.0 vs.
3.790.9 respectively, p<0.01). Patients consigned to CABG more often presented
with triple and LMD (82.2 vs. 33.8% and 13.7 vs. 2.4%; p<0.01). Otherwise,
proximal LAD was more often stented (21.5 vs. 11.1%; p<0.01). After adjustment
929 well-matched pairs were selected. Early mortality was lower after PCI prior to
matching (2.1 vs. 3.1%; p<0.01), whereas after balancing, no difference was found
(2.5 vs. 2.8%; p¼0.62). Three year survival was in favor of PCI when compared to
surgery prior (87.5 vs. 82.8%, HR: 1.44, 95%CI: 1.2-1.7) and after matching (86.4 vs.
82.3%, HR 1.33, 95%CI:1.05-1.7 and p¼0.01). Stenting was associated withacts/POSTER/STEMI/NSTEMI/ACS B81
